Four-modality therapy in malignant pleural mesothelioma: A phase II study

Journal of Thoracic Oncology

Volumn 2, Issue 3, 2007, Pages 237-242

  Lucchi, Marco ^a   Chella, Antonio ^a   Melfi, Franca ^a   Dini, Paolo ^a   Tibaldi, Carmelo ^b   Fontanini, Gabriella ^a   Mussi, Alfredo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Livorno Hospital   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Mesothelioma; Multimodality treatments; Pleurectomy

Indexed keywords

ANTIPYRETIC AGENT; CISPLATIN; EPIRUBICIN; GEMCITABINE; INTERLEUKIN 2; PARACETAMOL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; EOSINOPHILIA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LONG TERM CARE; MALE; MALIGNANT MESOTHELIOMA; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PLEURECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SKIN EXFOLIATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THORACOSCOPY; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT THERAPY; FEASIBILITY STUDY; MESOTHELIOMA; MIDDLE AGED; PLEURA; PLEURA TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURA; PLEURAL NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 34247163609     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318031d05c     Document Type: Article

References (23)

1. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001;78:171-174.
2. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-1185.
3. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med 2006;27:335-354.
4. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004;126:1318-29.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
6. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
7. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-758.
8. Grande C, Firvida JL, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 2006;17:1-12.
9. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001;31:303-310.
10. Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 2001;31:67-72.
11. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/ decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994;12:1156-1163.
12. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
13. Rice TW, Adelstein DJ, Kirby TJ, et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994;58:24-29.
14. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124:1183-1189.
15. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
16. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992;10:824-828.
17. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE) - Mesothelioma Committee. Tumori 1991;77:49-51.
18. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
19. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-1052.
20. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006;24:1561-1567.
21. Broomfield S, Currie A, van der Most RG, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005;65:7580-7584.
22. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457.
23. Stahel R, Weder W. Neoadjuvant chemotherapy in malignant pleural mesothelioma. Lung Cancer 2005;49(suppl 1):S69-S70.